New hope for hepatitis c: triple therapy shows promise in untreated patients
NCT ID NCT00780416
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new drug called MP-424 (Telaprevir) added to the standard two-drug therapy for hepatitis C. It involved 189 adults with genotype 1 hepatitis C who had never been treated before. The goal was to see if the triple combination could clear the virus from the blood for at least 24 weeks after treatment ended.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Telaprevir (MP-424) combined with peginterferon alfa-2b and ribavirin
What this could lead to
If successful, this could lead to a more effective treatment for hepatitis C, helping more patients clear the virus.
What could go wrong
This is a completed Phase 3 trial, but results may not apply to all patients, and side effects from the drug combination can be significant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATITIS C are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Toranomon Hospital
Kawasaki, Takatsu-ku, Japan